NeuroStar Advanced Therapy Wins 2023 Bulldog PR Award For Partnership With Drew Robinson, Mental Health Advocate and Former MLB Player
11 Julho 2023 - 9:56AM
Neuronetics, Inc. (NASDAQ: STIM), a medical technology company
focused on designing, developing, and marketing products that
improve the quality of life for patients who suffer from
neurohealth disorders, is thrilled to announce that its partnership
with Drew Robinson in 2022 has been awarded Gold for Best Use of
Personality/Celebrity at the 2023 Bulldog PR Awards.
“We are immensely honored to receive this recognition from the
Bulldog PR Awards. Drew Robinson is an inspiring mental health
advocate, and we share his passion for increasing awareness. Our
partnership enabled us to reach a broader audience and educate
people about the transformative benefits of NeuroStar TMS,” stated
Keith J. Sullivan, President, and CEO of Neuronetics Inc. “This
award is a testament to the powerful impact we can make when we
collaborate with influential figures like Drew, who are committed
to making a difference and empowering patients to seek an
effective, non-drug treatment option.”
The Bulldog PR Awards honor outstanding corporate communications
and public relations achievements, recognizing excellence and
innovation. Distinguished by their unique approach, they are the
only PR awards program evaluated solely by journalists.
Major depressive disorder (MDD) is a serious issue that affects
21 million adults in the United States, with 6.4 million people
being underserved by antidepressant medication. NeuroStar TMS
(transcranial magnetic stimulation) is a non-drug treatment that
can help alleviate the burden of drug-resistant depression.
To sign up for the Bulldog newsletter, please visit the website.
For more information about NeuroStar TMS Therapy, please
visit NeuroStar.com.
About NeuroneticsNeuronetics,
Inc. believes that mental health is as important as physical
health. As a global leader in
neuroscience, Neuronetics is redefining patient and
physician expectations with its NeuroStar Advanced Therapy for
Mental Health. NeuroStar is a non-drug, noninvasive treatment that
can improve the quality of life for people suffering from
neurohealth conditions when traditional medication hasn’t helped.
NeuroStar is FDA-cleared for adults with major depressive disorder
(MDD), as an adjunct for adults with obsessive-compulsive disorder
(OCD), and to decrease anxiety symptoms in adult patients with MDD
that may exhibit comorbid anxiety symptoms (anxious depression).
NeuroStar Advanced Therapy is the leading transcranial magnetic
stimulation (TMS) treatment for MDD in adults with over 5.4 million
treatments delivered. NeuroStar is backed by the largest clinical
data set of any TMS system for depression, including the world’s
largest depression Outcomes Registry. Neuronetics is
committed to transforming lives by offering an exceptional
treatment that produces extraordinary results. For safety and
prescribing
information, www.neurostar.com.
Media
Contact:EvolveMKD646.517.4220NeuroStar@evolvemkd.com
Neuronetics (NASDAQ:STIM)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Neuronetics (NASDAQ:STIM)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024